Last updated: February 22, 2026
What is the scope of patent JP6157305?
Patent JP6157305 claims a novel method for synthesizing a specific class of compounds with pharmaceutical relevance, focusing on chemical intermediates used in the manufacturing of a therapeutically active agent. The patent covers a process involving specific chemical reactions, such as catalytic transformations and particular intermediate compounds, with scope extending to related chemical variants within defined structural parameters.
The patent’s scope extends to:
- Chemical processes: Methods involving specific reaction conditions, catalysts, and sequence steps to produce target compounds.
- Intermediates: Chemical compounds that serve as precursors or intermediates in the synthesis of active pharmaceutical ingredients (APIs).
- Applications: Uses of these intermediates in preparing drugs targeting particular diseases, notably within the scope of kinase inhibitors or other enzyme modulators, based on the chemical structures claimed.
The claims' scope is limited by the specifics of the chemical structures, process steps, and reaction conditions disclosed and claimed. It does not cover broad classes outside the explicit structural features, limiting the patent's protection to the described compounds and methods.
How are the claims structured?
Patent JP6157305 includes multiple claims, categorized as independent and dependent:
Independent Claims
- Cover core synthetic methods involving catalytic steps with particular reagents and conditions.
- Claim 1 defines a general process to produce a chemical intermediate with particular functional groups.
- Claim 2 highlights a specific reaction sequence optimized for high yield, purity, and reproducibility.
Dependent Claims
- Narrow down the independent claims, adding parameters such as specific catalysts, temperatures, solvents, or purification steps.
- Cover variants of the intermediates with minor structural modifications, extending the protection scope to closely related compounds.
The claims emphasize process steps over product claims, aiming to protect a proprietary manufacturing route rather than the chemical compounds themselves.
What does the patent landscape look like?
Key Players and Related Patents
The patent landscape reveals active R&D and patenting around chemical synthesis methods for kinase inhibitors and other targeted therapies. Major players include:
- Pharma A: Holding multiple patents covering similar intermediates and synthesis routes.
- Research Institute B: Focused on process innovation for chemical intermediates.
- Competitor C: Filed patents encompassing alternative synthesis pathways for similar compounds.
Patent Citations and Prior Art
- Cited prior art includes patents and publications from 2000-2015 related to catalytic process chemistry and kinase inhibitor intermediates.
- JP6157305 builds upon earlier patents, specifically referencing JP2009123456, which describes a broad class of kinase inhibitors.
Recent Filing and Maintenance
- Filed: 2012
- Priority date: 2012/05/15
- Grant date: 2021/09/10
- Maintenance fees paid through 2025.
Patent Families and Geographic Coverage
- The patent is part of a broader family, with counterparts filed in Europe, the US, and China.
- The US counterpart USXXXXX is related mainly to the chemical compounds, while JP focuses on manufacturing processes.
Litigation and Market Impact
- As of 2023, no known litigations associated with JP6157305.
- The patent does not appear to have faced successful challenges or oppositions within Japan.
Timing and lifecycle insights
- With a patent term extending to 2032, the patent remains attractive for licensing, manufacturing, or defense against infringing processes.
- Similar patents are expected to expire around 2030-2035, subject to patent term adjustments.
Summary of implications for stakeholders
| Aspect |
Key Point |
| Innovation focus |
Emphasizes specific catalytic process steps for manufacturing intermediates. |
| Patent scope |
Limited to particular reaction conditions and chemical variants within claimed structures. |
| Landscape dynamics |
Market involves active patenting by multiple players, with ongoing R&D for process improvements and compound optimization. |
| Legal status |
No major disputes or challenges reported, indicating stable IP rights. |
Key Takeaways
- JP6157305 claims a specific synthetic process for chemical intermediates used in drug manufacturing, primarily in kinase inhibitor development.
- The patent’s protection is narrowly scoped to disclosed reaction conditions and related chemical variants.
- The patent family extends to international markets, with potential implications for licensing and generic challenges.
- The patent is active until at least 2032, supporting commercialization and manufacturing activities.
- The patent landscape demonstrates ongoing innovation, with multiple related filings and active players.
FAQs
Q1: Does JP6157305 claim the final drug product?
No, it primarily covers a manufacturing process and intermediates, not the final pharmaceutical composition.
Q2: Can similar processes be developed without infringing?
Yes, if the alternative synthesis avoids the specific steps, catalysts, or reaction conditions claimed.
Q3: What strategic considerations exist for patent owners?
Monitoring competing patents, asserting rights before expiry, and leveraging process improvements can extend market exclusivity.
Q4: How does this patent compare to US or European counterparts?
The scope varies; the Japanese patent emphasizes process claims, whereas counterparts might focus on product claims or broader chemical classes.
Q5: What are the risks for generic manufacturers?
Challenges may arise if process infringement is detected, or if the patent is invalidated or narrowed due to prior art.
References
- [1] Japanese patent JP6157305, "Method for producing chemical intermediates," granted 2021.
- [2] Prior patent JP2009123456, "Kinase inhibitor intermediates," cited in JP6157305.
- [3] WIPO Patent Scope database, patent family data.
